Open AccessHydroxychloroquine-induced podocytopathy mimicking Fabry disease
Author(s) -
Justine Serre,
David Buob,
JeanJacques Boffa
Publication year - 2019
Publication title -
bmj case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.231
H-Index - 26
ISSN - 1757-790X
DOI - 10.1136/bcr-2018-228876
Subject(s) - hydroxychloroquine , medicine , fabry disease , rheumatoid arthritis , systemic disease , phospholipidosis , pathology , disease , proteinuria , dermatology , kidney , phospholipid , covid-19 , membrane , biology , infectious disease (medical specialty) , genetics
Hydroxychloroquine (HCQ) is largely prescribed as an immunomodulator to prevent systemic diseases flares in patients with systemic lupus erythematous, rheumatoid arthritis, Sjogren's disease. Among reported side effects, HCQ can accumulate in lysosomes and induced phospholipidosis. Here, we report an HCQ-induced podocytopathy mimicking Fabry disease (FD). They share the same histological lesions: cytoplasmic vacuolisation of the podocytes and zebra bodies on light and electronic microscopy. FD has been ruled out by measuring enzymatic activity and genetic test. The persistence of proteinuria after immunological remission of a systemic disease treated with HCQ could suggest this HCQ-induced podocytopathy.